Article excerpt
Highlighted: the sentence this signal was extracted from
Basel, November 12, 2026 – Novartis today announced 52-week results from the Phase III RemIND program evaluating Rhapsido ® (remibrutinib) in chronic inducible urticaria (CIndU). In the long-term analysis from the RemIND study, Rhapsido 25 mg twice daily showed early and sustained efficacy through Week 52 in patients across the three most prevalent CIndU subtypes: symptomatic dermographism (SD), cold urticaria (ColdU) and cholinergic urticaria (CholU). 1 The data will be presented as a late-breaking abstract at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting 2026.